Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria.
BACKGROUND: Fears of emerging artemisinin resistance in western Cambodia have prompted a series of clinical trials investigating whether slow responses to antimalarial treatment can be overcome by increasing doses of drug. METHODS: Patients with uncomplicated malaria were allocated 1 of 3 oral arte...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1826261282058141696 |
|---|---|
| author | Bethell, D Se, Y Lon, C Socheat, D Saunders, D Teja-Isavadharm, P Khemawoot, P Darapiseth, S Lin, J Sriwichai, S Kuntawungin, W Surasri, S Lee, S Sarim, S Tyner, S Smith, B Fukuda, M |
| author_facet | Bethell, D Se, Y Lon, C Socheat, D Saunders, D Teja-Isavadharm, P Khemawoot, P Darapiseth, S Lin, J Sriwichai, S Kuntawungin, W Surasri, S Lee, S Sarim, S Tyner, S Smith, B Fukuda, M |
| author_sort | Bethell, D |
| collection | OXFORD |
| description | BACKGROUND: Fears of emerging artemisinin resistance in western Cambodia have prompted a series of clinical trials investigating whether slow responses to antimalarial treatment can be overcome by increasing doses of drug. METHODS: Patients with uncomplicated malaria were allocated 1 of 3 oral artesunate monotherapy regimens (2, 4, or 6 mg/kg/day for 7 days) and were observed for 42 days. A series of safety measures, including complete blood count on days 0, 3, 6, and 14, was implemented because of a lack of safety data for these experimental doses. RESULTS: After 3 doses, geometric mean absolute neutrophil counts were reduced in all groups, and 2 patients required artesunate to be discontinued because of neutropenia (absolute neutrophil count, <1.0 × 10(3) cells/μL). Recipients of the 6 mg/kg/day dosage had significantly lower geometric mean absolute neutrophil counts than did recipients of the 2 and 4 mg/kg/day dosages at 6 and 14 days (P < .001 for each). Overall, 5 (19%) of 26 patients who received the 6 mg/kg/day dosage became neutropenic within 14 days, triggering a cohort-halting rule and ending the trial early. Pharmacokinetic data from neutropenic patients showed wide variance, with plasma clearance occurring significantly slower in neutropenic patients than in nonneutropenic patients. CONCLUSIONS: Artesunate remains a crucial drug for the treatment of malaria, and determining optimal dosing regimens is vital to overcome emerging resistant parasite strains along the Thai-Cambodian border. However, future experimental dosing studies must be designed with care, because the safety of such regimens can no longer be assumed. The artemisinin derivatives remain one of the safest classes of antimalarial drugs, but this study demonstrates that the dosing limit may have been reached. |
| first_indexed | 2024-03-06T19:18:59Z |
| format | Journal article |
| id | oxford-uuid:196624bc-137b-4c68-9ef8-a098ed6f9868 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:18:59Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:196624bc-137b-4c68-9ef8-a098ed6f98682022-03-26T10:48:50ZDose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:196624bc-137b-4c68-9ef8-a098ed6f9868EnglishSymplectic Elements at Oxford2010Bethell, DSe, YLon, CSocheat, DSaunders, DTeja-Isavadharm, PKhemawoot, PDarapiseth, SLin, JSriwichai, SKuntawungin, WSurasri, SLee, SSarim, STyner, SSmith, BFukuda, M BACKGROUND: Fears of emerging artemisinin resistance in western Cambodia have prompted a series of clinical trials investigating whether slow responses to antimalarial treatment can be overcome by increasing doses of drug. METHODS: Patients with uncomplicated malaria were allocated 1 of 3 oral artesunate monotherapy regimens (2, 4, or 6 mg/kg/day for 7 days) and were observed for 42 days. A series of safety measures, including complete blood count on days 0, 3, 6, and 14, was implemented because of a lack of safety data for these experimental doses. RESULTS: After 3 doses, geometric mean absolute neutrophil counts were reduced in all groups, and 2 patients required artesunate to be discontinued because of neutropenia (absolute neutrophil count, <1.0 × 10(3) cells/μL). Recipients of the 6 mg/kg/day dosage had significantly lower geometric mean absolute neutrophil counts than did recipients of the 2 and 4 mg/kg/day dosages at 6 and 14 days (P < .001 for each). Overall, 5 (19%) of 26 patients who received the 6 mg/kg/day dosage became neutropenic within 14 days, triggering a cohort-halting rule and ending the trial early. Pharmacokinetic data from neutropenic patients showed wide variance, with plasma clearance occurring significantly slower in neutropenic patients than in nonneutropenic patients. CONCLUSIONS: Artesunate remains a crucial drug for the treatment of malaria, and determining optimal dosing regimens is vital to overcome emerging resistant parasite strains along the Thai-Cambodian border. However, future experimental dosing studies must be designed with care, because the safety of such regimens can no longer be assumed. The artemisinin derivatives remain one of the safest classes of antimalarial drugs, but this study demonstrates that the dosing limit may have been reached. |
| spellingShingle | Bethell, D Se, Y Lon, C Socheat, D Saunders, D Teja-Isavadharm, P Khemawoot, P Darapiseth, S Lin, J Sriwichai, S Kuntawungin, W Surasri, S Lee, S Sarim, S Tyner, S Smith, B Fukuda, M Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. |
| title | Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. |
| title_full | Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. |
| title_fullStr | Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. |
| title_full_unstemmed | Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. |
| title_short | Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. |
| title_sort | dose dependent risk of neutropenia after 7 day courses of artesunate monotherapy in cambodian patients with acute plasmodium falciparum malaria |
| work_keys_str_mv | AT bethelld dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT sey dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT lonc dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT socheatd dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT saundersd dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT tejaisavadharmp dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT khemawootp dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT darapiseths dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT linj dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT sriwichais dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT kuntawunginw dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT surasris dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT lees dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT sarims dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT tyners dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT smithb dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria AT fukudam dosedependentriskofneutropeniaafter7daycoursesofartesunatemonotherapyincambodianpatientswithacuteplasmodiumfalciparummalaria |